How We're Keeping You Safe | What Patients & Families Need to Know
Following two decades of research on a group of rare diseases called hypereosinophilic syndrome, the U.S. Food and Drug Administration has approved the drug Nucala (mepolizumab) for use in the treatment of patients with hypereosinophilic syndrome.
Scientists use human intestinal organoids grown from stem cells to discover how our bodies control the absorption of nutrients from the food we eat.
Study reports neurons inside our brains express a protein that can detect a specific wavelength of light from the sun. Those neurons send signals that influence a number of our body functions—including our metabolism.
Designed for use by people aged 13 and above, this artificial intelligence (AI)-powered chat bot engages in conversations with users, serving as a digital mental health coach.
Findings from expert at Cincinnati Children’s suggest new approaches for treating inflammatory bowel diseases.
A surprising new concept for boosting the power of flu vaccines might also boost future COVID-19 vaccines.
The funding will be shared by a coordinating center and a network of 10 other top academic medical centers that will launch a five-year effort to improve genomic risk assessments for diverse populations and integrate their use in clinical care.
Researchers find that dose escalation of hydroxyurea treatment for children in Uganda with sickle cell anemia is more effective than a lower fixed dose of the same drug.
A transgenic mouse developed at Cincinnati Children’s to model the deadly childhood immune disease HLH (hemophagocytic lymphohistiocytosis) may play a key role in saving lives during the COVID-19 virus pandemic.
Selected as part of an international search that included a broad field of high-caliber candidates in pediatric medicine, Cheng comes from Johns Hopkins Hospital and the Johns Hopkins College of Medicine.
The projects, funded internally, will focus on developing vaccine nanoparticles, studying how the virus affects heart tissue, an artificial intelligence data analysis tool, and how COVID-19 affects foster youth, ADHD, and sickle cell disease.
Prompted by COVID-19 clinic closures, scientists developed the mail-in test so medically vulnerable patients can receive regular testing without the need for clinical visits.
Researchers report in the New England Journal of Medicine treating patients with a new drug called emapalumab that saves kid’s lives with less toxicity and fewer side effects.
Cincinnati Children’s is one of four sites in the U.S. participating in a Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19.
AI system uses pattern-recognizing machine learning and natural language processing (NLP) technologies to predict youth’s risk for committing actions of school violence.
New research in PLoS Pathogens suggests that reactivated Herpes Simplex Virus (HSV) in trigeminal nerves of laboratory mice kills off at least a portion of sensory neurons.
Cincinnati Children’s researchers report in Immunity the discovery of a complex biological process that helps underdeveloped lungs fight infections.
The Cincinnati Children's 2019 Research Annual Report features the most significant findings of the year from more than 50 research divisions.
A new study suggests that significant early childhood exposure to traffic-related air pollution (TRAP) is associated with structural changes in the brain at the age of 12.
Being the parent of a child with a life-altering chronic condition takes a psychological toll. For too many families, however, emotional and behavioral health support has been far too difficult to obtain.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026 | 1-513-636-4200 | 1-800-344-2462
© 1999-2020 Cincinnati Children's Hospital Medical Center. All rights reserved.